Skip to main content
Top
Published in: Supportive Care in Cancer 2/2009

01-02-2009 | Review Article

Decision making and quality of life in the treatment of cancer: a review

Authors: S. Yousuf Zafar, Stewart C. Alexander, Kevin P. Weinfurt, Kevin A. Schulman, Amy P. Abernethy

Published in: Supportive Care in Cancer | Issue 2/2009

Login to get access

Abstract

Introduction

Complexity in decision making for cancer treatment arises from many factors. When considering how to treat patients, physicians prioritize factors such as stage of disease, patient age, and comorbid illnesses. However, physicians must balance these priorities with the patient’s preferences, quality of life, social responsibilities, and fear of uncertainty. Although these factors are important, physicians are often unable to effectively judge their patients’ preferences. Patients are often unable to fully understand their prognoses and the treatment intent.

Discussion

These differences influence how patients and physicians make treatment-related decisions. Partially due to these differences, patients are initially more likely than their physicians to accept greater risk for lesser benefit from treatment. As time progresses and as they experience treatment, a patient’s preference changes, yet little is known about this process since few studies have examined it in a prospective longitudinal manner. We present an overview of the literature related to patient and physician decision making and quality of life in patients with advanced cancer, and we propose approaches to future decision-making models in cancer treatment.
Literature
1.
go back to reference Au H, Karapetis C, Jonker D, O’Callaghan C, Kennecke H, Shapiro J (2007) Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 25:4002 2007 ASCO Annual Meeting Proc Au H, Karapetis C, Jonker D, O’Callaghan C, Kennecke H, Shapiro J (2007) Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 25:4002 2007 ASCO Annual Meeting Proc
2.
3.
go back to reference Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA et al (2005) Explaining black–white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211–1220PubMedCrossRef Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA et al (2005) Explaining black–white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211–1220PubMedCrossRef
5.
go back to reference Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S (2001) Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 19:2883–2885PubMed Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S (2001) Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 19:2883–2885PubMed
6.
go back to reference Bui L, Rempel E, Reeson D, Simunovic M (2006) Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 93:439–445 doi:10.1002/jso.20499 PubMedCrossRef Bui L, Rempel E, Reeson D, Simunovic M (2006) Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 93:439–445 doi:10.​1002/​jso.​20499 PubMedCrossRef
7.
go back to reference Cassileth BR, Zupkis RV, Sutton-Smith K, March V (1980) Information and participation preferences among cancer patients. Ann Intern Med 92:832–836PubMed Cassileth BR, Zupkis RV, Sutton-Smith K, March V (1980) Information and participation preferences among cancer patients. Ann Intern Med 92:832–836PubMed
8.
go back to reference Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18:421–428PubMed Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18:421–428PubMed
9.
go back to reference Colorectal Cancer Collaborative Group (2000) Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356:968–974CrossRef Colorectal Cancer Collaborative Group (2000) Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356:968–974CrossRef
10.
go back to reference Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197 doi:10.1200/JCO.2006.08.8005 PubMedCrossRef Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197 doi:10.​1200/​JCO.​2006.​08.​8005 PubMedCrossRef
11.
go back to reference Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14 doi:10.2307/3564113 PubMedCrossRef Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14 doi:10.​2307/​3564113 PubMedCrossRef
13.
go back to reference Demissie K, Oluwole OO, Balasubramanian BA, Osinubi OO, August D, Rhoads GG (2004) Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between Whites and Blacks. Ann Epidemiol 14:215–221PubMedCrossRef Demissie K, Oluwole OO, Balasubramanian BA, Osinubi OO, August D, Rhoads GG (2004) Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between Whites and Blacks. Ann Epidemiol 14:215–221PubMedCrossRef
14.
go back to reference Du XL, Fang S, Vernon SW, El-Serag H, Shih YT, Davila J et al (2007) Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660–669 doi:10.1002/cncr.22826 PubMedCrossRef Du XL, Fang S, Vernon SW, El-Serag H, Shih YT, Davila J et al (2007) Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660–669 doi:10.​1002/​cncr.​22826 PubMedCrossRef
15.
go back to reference Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D (2007) Desire for information and involvement in treatment decisions: elderly cancer patients’ preferences and their physicians’ perceptions. J Clin Oncol 25:5275–5280 doi:10.1200/JCO.2007.11.1922 PubMedCrossRef Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D (2007) Desire for information and involvement in treatment decisions: elderly cancer patients’ preferences and their physicians’ perceptions. J Clin Oncol 25:5275–5280 doi:10.​1200/​JCO.​2007.​11.​1922 PubMedCrossRef
16.
go back to reference Eng C, Maurel J, Scheithauer W, Wong L, Lutz M, Middleton G (2007) Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 25:4003 2007 ASCO Annual Meeting Proc Eng C, Maurel J, Scheithauer W, Wong L, Lutz M, Middleton G (2007) Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 25:4003 2007 ASCO Annual Meeting Proc
18.
21.
go back to reference Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091 doi:10.1200/JCO.2006.06.9039 PubMedCrossRef Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091 doi:10.​1200/​JCO.​2006.​06.​9039 PubMedCrossRef
23.
24.
go back to reference Grossman M (1972) On the concept of health capital and the demand for health. J Pol Econ 80:168–199 Grossman M (1972) On the concept of health capital and the demand for health. J Pol Econ 80:168–199
26.
go back to reference Harrison LE, Guillem JG, Paty P, Cohen AM (1997) Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 185:55–59PubMed Harrison LE, Guillem JG, Paty P, Cohen AM (1997) Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 185:55–59PubMed
28.
29.
go back to reference Kiebert GM, Stiggelbout AM, Kievit J, Leer JW, van de Velde CJ, de Haes HJ (1994) Choices in oncology: factors that influence patients’ treatment preference. Qual Life Res 3:175–182 doi:10.1007/BF00435382 PubMedCrossRef Kiebert GM, Stiggelbout AM, Kievit J, Leer JW, van de Velde CJ, de Haes HJ (1994) Choices in oncology: factors that influence patients’ treatment preference. Qual Life Res 3:175–182 doi:10.​1007/​BF00435382 PubMedCrossRef
30.
go back to reference Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB et al (2001) Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812–823PubMed Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB et al (2001) Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812–823PubMed
33.
go back to reference Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna SS, Khalifa M et al (2003) Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage II colon cancer. J Surg Oncol 84:120–126 doi:10.1002/jso.10309 PubMedCrossRef Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna SS, Khalifa M et al (2003) Impact of lymph node retrieval and pathological ultra-staging on the prognosis of stage II colon cancer. J Surg Oncol 84:120–126 doi:10.​1002/​jso.​10309 PubMedCrossRef
35.
go back to reference Love N, Bylund C, Meropol NJ, Marshall JL, Curley SA, Ellis LM (2007) How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. J Clin Oncol 25:4020 2007 ASCO Annual Meeting Proc Part I Love N, Bylund C, Meropol NJ, Marshall JL, Curley SA, Ellis LM (2007) How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. J Clin Oncol 25:4020 2007 ASCO Annual Meeting Proc Part I
36.
go back to reference Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS (1988) Cancer patients’ perceptions of their disease and its treatment. Br J Cancer 58:355–358PubMed Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS (1988) Cancer patients’ perceptions of their disease and its treatment. Br J Cancer 58:355–358PubMed
38.
go back to reference Maly RC, Umezawa Y, Ratliff CT, Leake B (2006) Racial/ethnic group differences in treatment decision-making and treatment received among older breast carcinoma patients. Cancer 106:957–965 doi:10.1002/cncr.21680 PubMedCrossRef Maly RC, Umezawa Y, Ratliff CT, Leake B (2006) Racial/ethnic group differences in treatment decision-making and treatment received among older breast carcinoma patients. Cancer 106:957–965 doi:10.​1002/​cncr.​21680 PubMedCrossRef
39.
go back to reference Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB 3rd, Castel L et al (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596 doi:10.1200/JCO.2003.10.072 PubMedCrossRef Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB 3rd, Castel L et al (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596 doi:10.​1200/​JCO.​2003.​10.​072 PubMedCrossRef
41.
go back to reference Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed
42.
44.
go back to reference National Cancer Institute Surveillance Epidemiology and End Results (SEER) Program (2004) Median age of cancer patients at diagnosis, 2000–2004 by primary cancer site, race and sex. National Cancer Institute National Cancer Institute Surveillance Epidemiology and End Results (SEER) Program (2004) Median age of cancer patients at diagnosis, 2000–2004 by primary cancer site, race and sex. National Cancer Institute
45.
go back to reference O’Connor AM, Boyd NF, Warde P, Stolbach L, Till JE (1987) Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. J Chronic Dis 40:811–818 doi:10.1016/0021-9681(87)90133-0 PubMedCrossRef O’Connor AM, Boyd NF, Warde P, Stolbach L, Till JE (1987) Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. J Chronic Dis 40:811–818 doi:10.​1016/​0021-9681(87)90133-0 PubMedCrossRef
47.
go back to reference Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412–2418PubMed Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412–2418PubMed
49.
go back to reference Prehn AW, Topol B, Stewart S, Glaser SL, O’Connor L, West DW (2002) Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women. Cancer 95:2268–2275 doi:10.1002/cncr.10965 PubMedCrossRef Prehn AW, Topol B, Stewart S, Glaser SL, O’Connor L, West DW (2002) Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women. Cancer 95:2268–2275 doi:10.​1002/​cncr.​10965 PubMedCrossRef
53.
go back to reference Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB (2001) Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results–Medicare. J Clin Oncol 19:3712–3718PubMed Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB (2001) Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results–Medicare. J Clin Oncol 19:3712–3718PubMed
54.
go back to reference Schwartz CE, Sprangers MA (2002) An introduction to quality of life assessment in oncology: the value of measuring patient-reported outcomes. Am J Manag Care 8:S550–S559PubMed Schwartz CE, Sprangers MA (2002) An introduction to quality of life assessment in oncology: the value of measuring patient-reported outcomes. Am J Manag Care 8:S550–S559PubMed
55.
go back to reference Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146–152PubMed Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146–152PubMed
56.
go back to reference Solomon MJ, Pager CK, Keshava A, Findlay M, Butow P, Salkeld GP et al (2003) What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 46:1351–1357 doi:10.1007/s10350-004-6749-0 PubMedCrossRef Solomon MJ, Pager CK, Keshava A, Findlay M, Butow P, Salkeld GP et al (2003) What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 46:1351–1357 doi:10.​1007/​s10350-004-6749-0 PubMedCrossRef
57.
go back to reference Stiggelbout AM, Jansen SJ, Otten W, Baas-Thijssen MC, van Slooten H, van de Velde CJ (2007) How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making? Support Care Cancer 15:319–325 doi:10.1007/s00520-006-0149-z PubMedCrossRef Stiggelbout AM, Jansen SJ, Otten W, Baas-Thijssen MC, van Slooten H, van de Velde CJ (2007) How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making? Support Care Cancer 15:319–325 doi:10.​1007/​s00520-006-0149-z PubMedCrossRef
59.
62.
go back to reference Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd et al (2003) The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166–175 doi:10.1002/cncr.11483 PubMedCrossRef Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd et al (2003) The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166–175 doi:10.​1002/​cncr.​11483 PubMedCrossRef
64.
go back to reference Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13:1255–1264PubMed Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13:1255–1264PubMed
Metadata
Title
Decision making and quality of life in the treatment of cancer: a review
Authors
S. Yousuf Zafar
Stewart C. Alexander
Kevin P. Weinfurt
Kevin A. Schulman
Amy P. Abernethy
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 2/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0505-2

Other articles of this Issue 2/2009

Supportive Care in Cancer 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine